Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CD274 |
Clinical data | |
Trade names | Imfinzi |
Other names | MEDI4736, MEDI-4736 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617030 |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous |
Drug class | Immune checkpoint inhibitor[2] |
Legal status | |
Legal status | |
Chemical and physical data | |
Formula | C6502H10018N1742O2024S42 |
Molar mass | 146322.36 g·mol−1 |
Durvalumab, sold under the brand name Imfinzi, is a medication used to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).[5] Specifically it is used for cases that produce a protein known as PD-L1.[5] It is given by injection into a vein every two weeks.[5]
Common side effects include cough, tiredness, pneumonitis, hair loss, shortness of breath, nausea, and rash.[6] Other side effects may include immune-mediated damage.[6] Use in pregnancy may harm the baby.[6] It is a monoclonal antibody that attaches to and blocking programmed death-ligand 1 (PD-L1).[5] This results in the immune system being able to attack the cells in question.[5]
Durvalumab was approved for medical use in the United States in 2017 and Europe in 2018.[5][7] In the United Kingdom 500 mg costs the NHS about £2,500 as of 2021.[8] This amount in the United States costs about US$3,900.[9]
References
edit- ^ a b "Durvalumab (Imfinzi) Use During Pregnancy". Drugs.com. 30 August 2019. Archived from the original on 29 August 2021. Retrieved 7 February 2020.
- ^ "durvalumab". www.cancer.gov. 2 February 2011. Archived from the original on 28 August 2021. Retrieved 27 December 2021.
- ^ "Imfinzi- durvalumab injection, solution". DailyMed. 5 June 2020. Archived from the original on 28 August 2021. Retrieved 30 September 2020.
- ^ "Imfinzi EPAR". European Medicines Agency (EMA). Archived from the original on 28 August 2021. Retrieved 30 September 2020.
- ^ a b c d e f g "Imfinzi". Archived from the original on 28 August 2021. Retrieved 27 December 2021.
- ^ a b c d "DailyMed - IMFINZI- durvalumab injection, solution". dailymed.nlm.nih.gov. Archived from the original on 28 August 2021. Retrieved 27 December 2021.
- ^ "Durvalumab Monograph for Professionals". Drugs.com. Archived from the original on 12 December 2021. Retrieved 27 December 2021.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 915. ISBN 978-0857114105.
- ^ "Imfinzi Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 10 May 2021. Retrieved 27 December 2021.